Intravenous immunoglobulin in the treatment of autoimmune bullous dermatoses: An update

References

• Murrell D, Dick S, Ahmed A, Amagia M, Barnadas M, Borradori L, Bystryn J, Cianchini G, Diaz L, Fivenson D. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol. 2008; 58 6: 1043–1046.
   PubMed Web of Science ®Google Scholar
• Ishii N, Hashimoto T, Zillikens D, Ludwig RJ. High-dose intravenous immunoglobulin (IVIG) therapy in autoimmune skin blistering diseases. Clin Rev Allergy Immunol. 2010; 38 2: 186–195.
   PubMed Web of Science ®Google Scholar
• Bystryn JC, Jiao D. IVIg selectively and rapidly decreases circulating pathogenic autoantibodies in pemphigus vulgaris. Autoimmunity. 2006; 39 7: 601–607.
   PubMed Web of Science ®Google Scholar
• Amagai M, Ikeda S, Shimizu H, Iizuka H, Hanada K, Aiba S, Kaneko F, Izaki S, Tamaki K, Ikezawa Z. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol. 2009; 60 4: 595–603.
   PubMed Web of Science ®Google Scholar
• Ahmed AR, Dahl MV. Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. Arch Dermatol. 2003; 139 8: 1051–1059.
   PubMedGoogle Scholar
• Harman K, Black M. High-dose intravenous immune globulin for the treatment of autoimmune blistering diseases: An evaluation of its use in 14 cases. Br J Dermatol. 1999; 140 5: 865–874.
   PubMed Web of Science ®Google Scholar
• Jolles S. A review of high-dose intravenous immunoglobulin (hdIVIg) in the treatment of the autoimmune blistering disorders. Clin Exp Dermatol. 2001; 26 2: 127–131.
   PubMed Web of Science ®Google Scholar
• Lolis M, Toosi S, Czernick A, Bystryn J. Effect of intravenous immunoglobulin with or without cytotoxic drugs on pemphigus intercellular antibodies. J Am Acad Dermatol. 2011; 64:484–489.
   PubMed Web of Science ®Google Scholar
• Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. New Engl J Med. 2006; 355 17: 1772–1779.
   PubMed Web of Science ®Google Scholar
• Joly P, Mouquet H, Roujeau JC, D'Incan M, Gilbert D, Jacquot S, Gougeon ML, Bedane C, Muller R, Dreno B. A single cycle of rituximab for the treatment of severe pemphigus. New Engl J Med. 2007; 357 6: 545–552.
   PubMed Web of Science ®Google Scholar
• Morrison LH. Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab). J Am Acad Dermatol. 2004; 51 5: 817–819.
   PubMed Web of Science ®Google Scholar
• Czernik A, Beutner E, Bystryn J. Intravenous immunoglobulin selectively decreases circulating autoantibodies in pemphigus. J Am Acad Dermatol. 2008; 58 5: 796–801.
   PubMed Web of Science ®Google Scholar
• Roujeau JC, Lok C, Bastuji-Garin S, Mhalla S, Enginger V, Bernard P. High risk of death in elderly patients with extensive bullous pemphigoid. Arch Dermatol. 1998; 134 4: 465–469.
   PubMedGoogle Scholar
• Ahmed A. Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol. 2001; 45 6: 825–835.
   PubMed Web of Science ®Google Scholar
• Sami N, Ali S, Bhol K, Ahmed A. Influence of intravenous immunoglobulin therapy on autoantibody titres to BP Ag1 and BP Ag2 in patients with bullous pemphigoid. J Eur Acad Dermatol Venereol. 2003; 17 6: 641–645.
   PubMed Web of Science ®Google Scholar
• Engineer L, Ahmed AR. Role of intravenous immunoglobulin in the treatment of bullous pemphigoid: Analysis of current data. J Am Acad Dermatol. 2001; 44 1: 83–88.
   PubMed Web of Science ®Google Scholar
• Czernik A, Bystryn J. Improvement of intravenous immunoglobulin therapy for bullous pemphigoid by adding immunosuppressive agents: Marked improvement in depletion of circulating autoantibodies. Arch Dermatol. 2008; 144 5: 658–661.
   PubMedGoogle Scholar
• Godard W, Roujeau J, Guillot B, Andre C, Rifle G. Bullous pemphigoid and intravenous gammaglobulin. Ann Intern Med. 1985; 103 6 Part 1: 964–965.
   PubMed Web of Science ®Google Scholar
• Tappeiner G, Steiner A. High-dosage intravenous gamma globulin: Therapeutic failure in pemphigus and pemphigoid. J Am Acad Dermatol. 1989; 20 4: 684–685.
   PubMed Web of Science ®Google Scholar
• Beckers R, Brand A, Vermeer B, Boom B. Adjuvant high-dose intravenous gammaglobulin in the treatment of pemphigus and bullous pemphigoid: Experience in six patients. Br J Dermatol. 1995; 133 2: 289–293.
   PubMed Web of Science ®Google Scholar
• Xiao T, Li B, Wang YK, He CD, Chen HD. Childhood bullous pemphigoid treated by iv immunoglobulin. J Dermatol. 2007; 34 9: 650–653.
   PubMed Web of Science ®Google Scholar
• Sugawara N, Nagai Y, Matsushima Y, Aoyama K, Ishikawa O. Infantile bullous pemphigoid treated with intravenous immunoglobulin therapy. J Am Acad Dermatol. 2007; 57 6: 1084–1089.
   PubMed Web of Science ®Google Scholar
• Urcelay M, McQueen A, Douglas W. Cicatricial pemphigoid treated with intravenous immunoglobulin. Br J Dermatol. 1997; 137 3: 477–478.
   PubMed Web of Science ®Google Scholar
• Ahmed AR, Colon JE. Comparison between intravenous immunoglobulin and conventional immunosuppressive therapy regimens in patients with severe oral pemphigoid: Effects on disease progression in patients nonresponsive to dapsone therapy. Arch Dermatol. 2001; 137 9: 1181–1189.
   PubMedGoogle Scholar
• Sami N, Letko E, Androudi S, Daoud Y, Foster C, Ahmed A. Intravenous immunoglobulin therapy in patients with ocular-cicatricial pemphigoid: A long-term follow-up. Ophthalmology. 2004; 111 7: 1380–1382.
   PubMed Web of Science ®Google Scholar
• Foster C, Ahmed A. Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: A preliminary study. Ophthalmology. 1999; 106 11: 2136–2143.
   PubMed Web of Science ®Google Scholar
• Segura S, Iranzo P, Pablo IM, Mascaró JMJr, Alsina M, Herrero J, Herrero C. High-dose intravenous immunoglobulins for the treatment of autoimmune mucocutaneous blistering diseases: Evaluation of its use in 19 cases. J Am Acad Dermatol. 2007; 56 6: 960–967.
   PubMed Web of Science ®Google Scholar
• Lagos J, Kemp S, Marshall G. Intravenous immune globulin in the treatment of ocular-cicatricial pemphigoid. J Allergy Clin Immunol. 2007; 119 Suppl. 1: S60.
   Web of Science ®Google Scholar
• Letko E, Miserocchi E, Daoud YJ, Christen W, Foster CS, Ahmed AR. A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies. Clin Immunol. 2004; 111 3: 303–310.
   PubMed Web of Science ®Google Scholar
• Mignogna MD, Leuci S, Piscopo R, Bonovolontà G. Intravenous immunoglobulins and mucous membrane pemphigoid. Ophthalmology. 2008; 115 4: 752.
   PubMed Web of Science ®Google Scholar
• Leverkus M, Georgi M, Nie Z, Hashimoto T, Bröcker EB, Zillikens D. Cicatricial pemphigoid with circulating IgA and IgG autoantibodies to the central portion of the BP180 ectodomain: Beneficial effect of adjuvant therapy with high-dose intravenous immunoglobulin. J Am Acad Dermatol. 2002; 46 1: 116–122.
   PubMed Web of Science ®Google Scholar
• Sami N, Bhol KC, Razzaque Ahmed A. Intravenous immunoglobulin therapy in patients with multiple mucosal involvement in mucous membrane pemphigoid. Clin Immunol. 2002; 102 1: 59–67.
   PubMed Web of Science ®Google Scholar
• Sami N, Bhol K, Ahmed A. Treatment of oral pemphigoid with intravenous immunoglobulin as monotherapy. Long term follow up: Influence of treatment on antibody titres to human 6 integrin. Clin Exp Immunol. 2002; 129 3: 533–540.
   PubMed Web of Science ®Google Scholar
• Uchino Y, Takahashi S, Uchino M, Shimazaki J. Combination treatment of intravenous immunoglobulin and cultivated oral mucosal epithelial transplantation for ocular cicatricial pemphigoid. Br Med J. 2007; 91 1: 117–118.
   Google Scholar
• Galdos M, Etxebarría J. Intravenous immunoglobulin therapy for refractory ocular cicatricial pemphigoid: Case report. Cornea. 2008; 27 8: 967–969.
   PubMed Web of Science ®Google Scholar
• Iaccheri B, Roque M, Fiore T, Papadaki T, Mathew B, Baltatzis S, Emara B, Tokarewicz A, Foster CS. Ocular cicatricial pemphigoid, keratomycosis, and intravenous immunoglobulin therapy. Cornea. 2004; 23 8: 819–822.
   PubMed Web of Science ®Google Scholar
• Gürcan H, Ahmed A. Intravenous immunoglobulin treatment in laryngeal pemphigoid. Clin Exp Dermatol. 2009; 34 8: 884–886.
   PubMed Web of Science ®Google Scholar
• Foster CS, Chang PY, Ahmed AR. Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: A preliminary report. Ophthalmology. 2010; 117 5: 861–869.
   PubMed Web of Science ®Google Scholar
• Ross A, Jaycock P, Cook S, Dick A, Tole D. The use of rituximab in refractory mucous membrane pemphigoid with severe ocular involvement. Br Med J. 2009; 93 4: 421–422.
   Google Scholar
• Schumann T, Schmidt E, Booken N, Goerdt S, Goebeler M. Successful treatment of mucous membrane pemphigoid with the anti-CD20 antibody rituximab. Acta Derm Venereol. 2009; 89 1: 101–102.
   PubMed Web of Science ®Google Scholar
• Taverna J, Lerner A, Bhawan J, Demierre M. Successful adjuvant treatment of recalcitrant mucous membrane pemphigoid with anti-CD20 antibody rituximab. J Drugs Dermatol. 2007; 6 7: 731–732.
   PubMedGoogle Scholar
• Schmidt E, Seitz C, Benoit S, Bröcker E, Goebeler M. Rituximab in autoimmune bullous diseases: Mixed responses and adverse effects. Br J Dermatol. 2007; 156 2: 352–356.
   PubMed Web of Science ®Google Scholar
• Campos M, Silvente C, Lecona M, Suárez R, Lázaro P. Epidermolysis bullosa acquisita: Diagnosis by fluorescence overlay antigen mapping and clinical response to high-dose intravenous immunoglobulin. Clin Exp Dermatol. 2006; 31 1: 71–73.
   PubMed Web of Science ®Google Scholar
• Tayal U, Burton J, Dash C, Wojnarowska F, Chapel H. Subcutaneous immunoglobulin therapy for immunomodulation in a patient with severe epidermolysis bullosa acquisita. Clin Immunol. 2008; 129 3: 518–519.
   PubMed Web of Science ®Google Scholar
• Caldwell J, Yancey K, Engler R, James W, Meier F, Sonnichsen K, Schaumburg-Lever G, Dopfer R, Rassner G. Epidermolysis bullosa aquisita: Efficacy of high-dose intravenous immunoglobulins. Author's reply. J Am Acad Dermatol. 1994; 31 5: 827–828.
   PubMed Web of Science ®Google Scholar
• Meier F, Sönnichsen K, Schaumburg-Lever G, Dopfer R, Rassner G. Epidermolysis bullosa acquisita: Efficacy of high-dose intravenous immunoglobulins. J Am Acad Dermatol. 1993; 29 2: 334–337.
   PubMed Web of Science ®Google Scholar
• Mohr C, Sunderkötter C, Hildebrand A, Biel K, Rütter A, Rütter G, Luger T, Kolde G. Successful treatment of epidermolysis bullosa acquisita using intravenous immunoglobulins. Br J Dermatol. 1995; 132 5: 82–86.
   Web of Science ®Google Scholar
• Kofler H, Wambacher-Gasser B, Topar G, Weinlich G, Schuler G, Hintner H, Romani N, Fritsch P. Intravenous immunoglobulin treatment in therapy-resistant epidermolysis bullosa acquisita. J Am Acad Dermatol. 1997; 36 2: 331–335.
   PubMed Web of Science ®Google Scholar
• Gourgiotou K, Exadaktylou D, Aroni K, Rallis E, Nicolaidou E, Paraskevakou H, Katsambas A. Epidermolysis bullosa acquisita: Treatment with intravenous immunoglobulins. J Eur Acad Dermatol Venereol. 2002; 16 1: 77–80.
   PubMed Web of Science ®Google Scholar
• Jappe U, Zillikens D, Bonnekoh B, Gollnick H. Epidermolysis bullosa acquisita with ultraviolet radiationsensitivity. Br J Dermatol. 2000; 142 3: 517–520.
   PubMed Web of Science ®Google Scholar
• Engineer L, Dow EC, Braverman IM, Ahmed AR. Epidermolysis bullosa acquisita and multiple myeloma* 1. J Am Acad Dermatol. 2002; 47 6: 943–946.
   PubMed Web of Science ®Google Scholar
• Kroiss M, Vogt T, Landthaler M, Stolz W. High dose intravenous immune globulin is also effective in linear IgA disease. Br J Dermatol. 2000; 142 3: 582.
   PubMed Web of Science ®Google Scholar
• Khan IU, Bhol KC, Ahmed AR. Linear IgA bullous dermatosis in a patient with chronic renal failure: Response to intravenous immunoglobulin therapy. J Am Acad Dermatol. 1999; 40 3: 485–488.
   PubMed Web of Science ®Google Scholar
• Letko E, Bhol K, Foster CS, Ahmed AR. Linear IgA bullous disease limited to the eye: A diagnostic dilemma 1: Response to intravenous immunoglobulin therapy. Ophthalmology. 2000; 107 8: 1524–1528.
   PubMed Web of Science ®Google Scholar
• Goebeler M, Seitz C, Rose C, Sitaru C, Jeschke R, Marx A, Bröcker E, Zillikens D. Successful treatment of linear IgA disease with salazosulphapyridine and intravenous immunoglobulins. Br J Dermatol. 2003; 149 4: 912–914.
   PubMed Web of Science ®Google Scholar
• Cauza K, Hinterhuber G, Sterniczky B, Brugger K, Pieczkowski F, Karlhofer F, Wolff K, Foedinger D. Unusual clinical manifestation of linear IgA dermatosis: A report of two cases* 1. J Am Acad Dermatol. 2004; 51 2: 112–117.
   Web of Science ®Google Scholar
• Kreuter A, Harati A, Breuckmann F, Appelhans C, Altmeyer P. Intravenous immune globulin in the treatment of persistent pemphigoid gestationis. J Am Acad Dermatol. 2004; 51 6: 1027–1028.
   PubMed Web of Science ®Google Scholar
• Hern S, Harman K, Bhogal B, Black M. A severe persistent case of pemphigoid gestationis treated with intravenous immunoglobulins and cyclosporin. Clin Exp Dermatol. 1998; 23 4: 185–188.
   PubMed Web of Science ®Google Scholar
• dos Santos Rodrigues C, Filipe P, del Mar Solana M, de Almeida LS, de Castro JC, Gomes MM. Persistent herpes gestationis treated with high-dose intravenous immunoglobulin. Acta Dermato-Venereol. 2007; 87 2: 184–186.
   PubMed Web of Science ®Google Scholar
• Li N, Zhao M, Hilario-Vargas J, Prisayanh P, Warren S, Diaz L, Roopenian D, Liu Z. Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. J Clin Invest. 2005; 115 12: 3440–3450.
   PubMed Web of Science ®Google Scholar
• Mimouni D, Blank M, Ashkenazi L, Milner Y, Frusic Zlotkin M, Anhalt G, David M, Shoenfeld Y. Protective effect of intravenous immunoglobulin (IVIG) in an experimental model of pemphigus vulgaris. Clin Exp Immunol. 2005; 142 3: 426–432.
   PubMed Web of Science ®Google Scholar
• Mimouni D, Blank M, Payne A, Anhalt G, Avivi C, Barshack I, David M, Shoenfeld Y. Efficacy of intravenous immunoglobulin (IVIG) affinity purified anti desmoglein anti idiotypic antibodies in the treatment of an experimental model of pemphigus vulgaris. Clin Exp Immunol. 2010; 162 3: 543–549.
   PubMed Web of Science ®Google Scholar
• Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, Hunziker T, Saurat J, Tschopp J, French L. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998; 282 5388: 490–493.
   PubMed Web of Science ®Google Scholar
• Orlov MD, Chernyavsky AI, Arredondo J, Grando SA. Synergistic actions of pemphigus vulgaris IgG, Fas-ligand and tumor necrosis factor-alpha during induction of basal cell shrinkage and acantholysis. Autoimmunity. 2006; 39 7: 557–562.
   PubMed Web of Science ®Google Scholar
• Arredondo J, Chernyavsky AI, Karaouni A, Grando SA. Novel mechanisms of target cell death and survival and of therapeutic action of IVIg in pemphigus. Am J Pathol. 2005; 167 6: 1531–1544.
   PubMed Web of Science ®Google Scholar
• Michael D, Grando SA. Novel mechanism for therapeutic action of IVIg in autoimmune blistering dermatoses. Curr Dir Autoimmun. 2008; 10:333–343.
   PubMedGoogle Scholar
• Pretel M, España A, Marquina M, Pelacho B, Lopez-Picazo J, Lopez-Zabalza M. An imbalance in Akt/mTOR is involved in the apoptotic and acantholytic processes in a mouse model of pemphigus vulgaris. Exp Dermatol. 2009; 18 9: 771–780.
   PubMed Web of Science ®Google Scholar
• Grando SA, Laquer VT, Le HM. Sirolimus for acute pemphigus vulgaris: A case report and discussion of dualistic action providing for both immunosuppression and keratinocyte protection. J Am Acad Dermatol. 2011 (in press) DOI: 10.1016/j.jaad.01.029.
   Web of Science ®Google Scholar
• Daoud YJ, Amin KG. Comparison of cost of immune globulin intravenous therapy to conventional immunosuppressive therapy in treating patients with autoimmune mucocutaneous blistering diseases. Int Immunopharmacol. 2006; 6 4: 600–606.
   PubMed Web of Science ®Google Scholar
• Gurcan HM, Ahmed AR. Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid. Ann Pharmacother. 2007; 41:1604–1610.
   PubMed Web of Science ®Google Scholar
• Hamrock DJ. Adverse events associated with intravenous immunoglobulin therapy. Int Immunopharmacol. 2006; 6 4: 535–542.
   PubMed Web of Science ®Google Scholar